EUVIMEDEUVIMED entdecken
Crossref

A dual-tracer approach for enhanced nodal staging in prostate cancer: the role of [18F]FDG PET/CT for detecting [68 Ga]Ga-PSMA-11-negative metastases

Ruohua Chen, Yining Wang, Liang Dong, Haitao Zhao, Lianghua Li, Gang Huang, Jianjun Liu

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-025-07683-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Ruohua Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Fluorodeoxyglucose F18, Edetic Acid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND PURPOSE: A subset of newly diagnosed prostate cancer patients harbor occult lymph node metastases (LNM) that are not detected by standard [68 Ga]Ga-PSMA-11 PET/CT, leading to potential understaging and suboptimal treatment planning. This study investigates the performance of [18F]FDG PET/CT as a secondary imaging tool to identify these PSMA-negative LNM. METHODOLOGY: We retrospectively analyzed 133 patients with newly diagnosed prostate cancer who were considered node-negative (miN0) by [68 Ga]Ga-PSMA-11 PET. All patients underwent a subsequent [18F]FDG PET/CT scan followed by radical prostatectomy and extended pelvic lymph node dissection (ePLND), with histopathology serving as the reference standard. The diagnostic efficacy of [18F]FDG PET/CT was benchmarked against the Briganti 2019 nomogram. RESULTS: Post-surgical pathology confirmed occult LNM in 11.3% (15/133) of patients. On a patient-based analysis, [18F]FDG PET/CT demonstrated a sensitivity of 73.3% and a specificity of 94.9% for detecting these occult LNM. This performance was significantly superior to the Briganti 2019 nomogram, with an area under the curve of 0.841 versus 0.621 (P < 0.001). Notably, multivariate analysis revealed that a lower serum prostate-specific antigen (PSA) level was an independent predictor of [18F]FDG-positive LNM (P = 0.013). CONCLUSIONS: In patients with newly diagnosed prostate cancer deemed node-negative by [68 Ga]Ga-PSMA-11 PET, supplementary [18F]FDG PET/CT can identify a significant proportion of occult LNM missed by initial staging. Our findings suggest that this dual-tracer approach may be particularly beneficial for patients with lower serum PSA levels, potentially improving risk stratification and selection for ePLND.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyProstatic NeoplasmsFluorodeoxyglucose F18Edetic AcidOligopeptidesHumansMaleLymphatic MetastasisAgedMiddle AgedRetrospective StudiesGallium RadioisotopesGallium IsotopesNeoplasm StagingRadioactive Tracers

Stichwörter der Autor:innen

Lymph node metastasesProstate cancer[18F]FDG[68 Ga]Ga-PSMA-11

Substanzen

Fluorodeoxyglucose F18gallium 68 PSMA-11Gallium RadioisotopesGallium IsotopesEdetic AcidOligopeptidesRadioactive TracersPSMA-11

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, China.
  • Department of Nuclear Medicine, School of Medicine, Ren Ji Hospital, Shanghai Jiao Tong University, Shanghai, China.
  • Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Department of Nuclear Medicine, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, China. huang2802@163.com.
  • Department of Nuclear Medicine, School of Medicine, Ren Ji Hospital, Shanghai Jiao Tong University, Shanghai, China. huang2802@163.com.
  • Department of Nuclear Medicine, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, China. nuclearj@163.com.

Zitieren

APA

Chen, R., Wang, Y., Dong, L., Zhao, H., Li, L., Huang, G., & Liu, J. (2026). A dual-tracer approach for enhanced nodal staging in prostate cancer: the role of [18F]FDG PET/CT for detecting [68 Ga]Ga-PSMA-11-negative metastases. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07683-4

Vancouver

Chen R, Wang Y, Dong L, Zhao H, Li L, Huang G, et al. A dual-tracer approach for enhanced nodal staging in prostate cancer: the role of [18F]FDG PET/CT for detecting [68 Ga]Ga-PSMA-11-negative metastases. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07683-4

BibTeX
@article{Chen2026,
  author = {Chen, Ruohua and Wang, Yining and Dong, Liang and Zhao, Haitao and Li, Lianghua and Huang, Gang and Liu, Jianjun},
  title = {A dual-tracer approach for enhanced nodal staging in prostate cancer: the role of [18F]FDG PET/CT for detecting [68 Ga]Ga-PSMA-11-negative metastases},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-025-07683-4}
}
Kostenlos starten →